112196-84-6

Upstream product

• 91475-01-3 methyl N-boc-D-ala-L-ala-O,N-dimethyl-L-tyr-L-alaninate 
• 3744-87-4 Boc-(R)-Ala 
• 73584-84-6 (S)-2-(tert-butoxycarbonyl(methyl)amino)-3-(4-methoxyphenyl)propanoic acid 
• 91474-97-4 methyl O,N-dimethyl-N-boc-L-tyr-L-alaninate 
• 69340-16-5 methyl L-ala-O,N-dimethyl-L-tyr-L-alaninate 
• 91475-00-2 methyl N-boc-L-ala-O,N-dimethyl-L-tyr-L-alaninate 
• 135103-27-4 C₁₆H₂₃NO₅*C₁₂H₂₃N 
• 71257-76-6 Boc-D-Ala-Ala-OMe 
• 112196-49-3 (S)-2-((R)-2-tert-butoxycarbonylamino-1-hydroxy-propylamino)-propionic acid 
• 91474-98-5 methyl O,N-dimethyl-L-tyr-L-alaninate 

Downstream Products

• 112196-81-3 BOC-D-Ala-L-Ala-NMe-L-Tyr(OMe)-L-Ala-OC₆F₅ 
• 135226-90-3 BOC-D-alanyl-L-alanyl-N,O-dimethyl-L-tyrosyl-L-alanyl-N-methyl-L-tyrosyl-N,O-dimethyl-L-tyrosine cyclic 5⁴<*>6³ ether, methyl ester 
• 112196-52-8 Boc-D-Ala-Ala-N-Me-Tyr(OMe)-N-Me-Gly-N-Me-Gly-OMe 
• 112196-74-4 3-(3-{4-[2-({(S)-2-[(S)-2-{[(S)-2-((R)-2-tert-Butoxycarbonylamino-propionylamino)-propionyl]-methyl-amino}-3-(4-methoxy-phenyl)-propionylamino]-propionyl}-methyl-amino)-ethyl]-phenoxy}-phenyl)-propionic acid methyl ester 
• 112196-61-9 Boc-D-Ala-Ala-N-Me-Tyr(OMe)-Ala-N-Me-Tyr-N-Me-Tyr-OMe 
• 138605-23-9 BOC-D-alanyl-L-alanyl-N,O⁴-dimethyl-L-tyrosyl-L-alanyl-L-tyrosyl-O⁴-methyl-L-tyrosine cyclic 5⁴<*>6³ ether, methyl ester 
• 138605-23-9 BOC-D-alanyl-L-alanyl-N,O-dimethyl-L-tyrosyl-L-alanyl-N-methyl-L-tyrosyl-O-methyl-L-tyrosine cyclic 5⁴<*>6³ ether, methyl ester 
• 1379654-52-0 C₅₂H₆₄N₆O₁₂ 
• 1379654-53-1 C₄₇H₅₄N₆O₉ 
• 1379654-43-9 C₄₀H₄₈N₆O₉ 
• 1372157-33-9 C₅₃H₆₈N₆O₁₁ 
• 1372157-31-7 [Tyr-5-ψ(CH2NMe)-Tyr-6]RA-VII 
• 112196-64-2 2-{[(S)-2-({(S)-2-[(S)-2-{[(S)-2-((R)-2-Amino-propionylamino)-propionyl]-methyl-amino}-3-(4-methoxy-phenyl)-propionylamino]-propionyl}-methyl-amino)-3-(4-hydroxy-phenyl)-propionyl]-methyl-amino}-3-(4-hydroxy-phenyl)-propionic acid; compound with trifluoro-acetic acid 

Relevant academic research and scientific papers

BOUVARDIN DERIVATIVES AND THERAPEUTIC USES THEREOF

The present invention is directed at bouvardin analogs arid related compounds for the treatment of disorders including cancer. Provided herein are bouvardin analogs and related compounds, pharmaceutical compositions and kits comprising at least one bouvar

Synthesis of [Tyr-5-Ψ(CH2NMe)-Tyr-6]RA-VII, a reduced peptide bond analogue of RA-VII, an antitumor bicyclic hexapeptide

A reduced peptide bond analogue of RA-VII, [Tyr-5-Ψ(CH 2NMe)-Tyr-6]RA-VII (3), was designed and synthesized. The key reduced cycloisodityrosine unit was prepared by reduction of the cycloisodityrosine derived from natural RA-VII, followed by co